Journals / Turkish Journal of Medical Sciences / 2003 / Cilt: 33 - Sayı: 6

A novel method of reporting c-erbB-2 overexpression: Correlation with grade but not with other prognostic parameters in breast cancer

Pages
363–369
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion reporting c-erbB-2 as a continuous variable may make more sense than treating a cut-off value as positive.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Overexpression of erbB-2 protein is a marker of clinically aggressive behavior in breast cancer patients.
📊
Key Findings & Data:In general erbB- 2 status is reported on a scale from negative to 3+, depending on staining intensity, if more than 10% of the tumor cells are stained.
💡
Conclusion & Impact:In conclusion reporting c-erbB-2 as a continuous variable may make more sense than treating a cut-off value as positive.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Overexpression of erbB-2 protein is a marker of clinically aggressive behavior in breast cancer patients. In general erbB- 2 status is reported on a scale from negative to 3+, depending on staining intensity, if more than 10% of the tumor cells are stained. However, the original definition does not take into account the percentage of stained cells in detail, since all samples score in the same way if they are above the cut-off, established at 10%. In this study, we evaluated the erB-B2 overexpression by immunohistochemistry in 169 patients and evaluated any correlation with the other well known prognostic parameters. We also tested whether there was a difference between the original definition of c-erbB-2 positivity (2+ or 3+) and a novel system, the total c-erbB-2 score, which takes into account both the percentage, and intensity of staining as a continuous variable. The total c-erbB-2 score was correlated with the grade (P = 0.006) but not with other parameters. When 2+ and 3+ levels of staining together were regarded as positive, a similar correlation with grade was demonstrated. However, when only 3+ cases were considered, there was no significant correlation. In conclusion reporting c-erbB-2 as a continuous variable may make more sense than treating a cut-off value as positive.

🔖

Cite This Article

SAMUR, M., PESTERELİ, E., BOZCUK, H., SAVAŞ, B., KARAVELİ, Ş., ÖZDOĞAN, M., ARTAÇ, M., YILDIZ, M. (2022). A novel method of reporting c-erbB-2 overexpression: Correlation with grade but not with other prognostic parameters in breast cancer. Turkish Journal of Medical Sciences, Cilt: 33 - Sayı: 6, 363–369. https://ajindex.com/articles/612106

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Neve RM, Lane HA, Hynes NE. The role of overexpressed Her2 in transformation. Annals Oncol 12 (suppl. 1): 9-13, 2001
  2. Bozcuk H, Uslu G, Pestereli E, et al. Predictors of distant metastasis at presentation in breast cancer: A study also evaluating associations among common biologic indicators. Breast Cancer Res Tr 68: 239-248, 2001
  3. Thor AD, Berry DA, Budman DR, et al. erbB-2, p53, and the efficacy of adjuvant therapy in lymph node positive breast cancer. J Natl Cancer Inst 90: 1346-1360, 1998
  4. Paik S, Bryant J, Park C et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive hormone receptornegative breast cancer. J Natl Cancer Inst 90: 1361-1370, 1998
  5. Yamauchi H, OÕNeill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels or extracellular domain of the Her- 2/c-neu protein. J Clin Oncol 15: 2518-2525, 1997
  6. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study. Clin Cancer Res 4: 7- 12, 1998
  7. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erbB-2 gene amplification and protein expression of human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238-1243, 1988
  8. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19: 403-10, 1991
  9. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association with overexpression with increased risk of recurrent disease. Cancer Res 53: 4960- 4970, 1993
  10. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904, 1997
  11. Idris N, Carothers Carraway CA, Carraway KL. Differential localization of ErbB2 in different tissues of the rat female reproductive tract: implications for the use of specific antibodies for ErbB2 analysis. J Cell Physiol 189: 162-70, 2001
  12. Menard S, Valagussa P, Pilotti S, et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph nodepositive breast cancer according to HER2 overexpression and other tumor biologic variables. J C